摘要
多倍体与细胞大小增加有关，并且通常存在于成人器官的子集和人胚胎的卵裂球阶段。 通过核内复制或细胞融合形成多倍体，以支持包括最早胚胎发生在内的特定发育需要。 最近的数据表明，多倍体巨细胞癌细胞（PGCCs）可能已经获得了一种活化的早期胚胎样程序，以响应致癌和治疗压力，从而产生用于药物抗性和转移的重编程癌细胞。 针对PGCC可能为癌症治疗开辟新的机会。
关键词: 多倍体巨细胞癌细胞，癌症干细胞，卵裂球样癌干细胞，核内复制，重编程，细胞融合。
图形摘要
[1]
Cronin, K.A.; Lake, A.J.; Scott, S.; Sherman, R.L.; Noone, A.M.; Howlader, N.; Henley, S.J.; Anderson, R.N.; Firth, A.U.; Ma, J.; Kohler, B.A.; Jemal, A. Annual report to the nation on the status of cancer, Part I: National Cancer Statistics. Cancer, 2018.
[2]
Weinberg, R.A. Coming full circle-from endless complexity to simplicity and back again. Cell, 2014, 157(1), 267-271.
[3]
Davoli, T.; de Lange, T. The causes and consequences of polyploidy in normal development and cancer. Annu. Rev. Cell Dev. Biol., 2011, 27, 585-610.
[4]
Fox, D.T.; Duronio, R.J. Endoreplication and polyploidy: Insights into development and disease. Development, 2013, 140(1), 3-12.
[5]
Orr-Weaver, T.L. When bigger is better: The role of polyploidy in organogenesis. Trends Genet., 2015, 31(6), 307-315.
[6]
Zielke, N.; Edgar, B.A.; DePamphilis, M.L. Endoreplication. Cold Spring Harb. Perspect. Biol., 2013, 5(1), a012948.
[7]
Lee, H.O.; Davidson, J.M.; Duronio, R.J. Endoreplication: Polyploidy with purpose. Genes Dev., 2009, 23(21), 2461-2477.
[8]
Ganem, N.J.; Pellman, D. Limiting the proliferation of polyploid cells. Cell, 2007, 131(3), 437-440.
[9]
Athayde Wirka, K.; Chen, A.A.; Conaghan, J.; Ivani, K.; Gvakharia, M.; Behr, B.; Suraj, V.; Tan, L.; Shen, S. Atypical embryo phenotypes identified by time-lapse microscopy: High prevalence and association with embryo development. Fertil. Steril., 2014, 101(6), 1637-1648.
[10]
Chavez, S.L.; Loewke, K.E.; Han, J.; Moussavi, F.; Colls, P.; Munne, S.; Behr, B.; Reijo, P.R.A. Dynamic blastomere behaviour reflects human embryo ploidy by the four-cell stage. Nat. Commun., 2012, 3, 1251.
[11]
Hardy, K.; Winston, R.M.; Handyside, A.H. Binucleate blastomeres in preimplantation human embryos in vitro: Failure of cytokinesis during early cleavage. J. Reprod. Fertil., 1993, 98(2), 549-558.
[12]
Iwata, K.; Yumoto, K.; Sugishima, M.; Mizoguchi, C.; Kai, Y.; Iba, Y.; Mio, Y. Analysis of compaction initiation in human embryos by using time-lapse cinematography. J. Assist. Reprod. Genet., 2014, 31(4), 421-426.
[13]
Kligman, I.; Benadiva, C.; Alikani, M.; Munne, S. The presence of multinucleated blastomeres in human embryos is correlated with chromosomal abnormalities. Hum. Reprod., 1996, 11(7), 1492-1498.
[14]
Van Royen, E.; Mangelschots, K.; Vercruyssen, M.; De Neubourg, D.; Valkenburg, M.; Ryckaert, G.; Gerris, J. Multinucleation in cleavage stage embryos. Hum. Reprod., 2003, 18(5), 1062-1069.
[15]
Voet, T.; Vanneste, E.; Van der Aa, N.; Melotte, C.; Jackmaert, S.; Vandendael, T.; Declercq, M.; Debrock, S.; Fryns, J.P.; Moreau, Y.; D’Hooghe, T.; Vermeesch, J.R. Breakage-fusion-bridge cycles leading to inv dup del occur in human cleavage stage embryos. Hum. Mutat., 2011, 32(7), 783-793.
[16]
Daughtry, B.L.; Chavez, S.L. Chromosomal instability in mammalian pre-implantation embryos: Potential causes, detection methods, and clinical consequences. Cell Tissue Res., 2016, 363(1), 201-225.
[17]
Eakin, G.S.; Hadjantonakis, A.K.; Papaioannou, V.E.; Behringer, R.R. Developmental potential and behavior of tetraploid cells in the mouse embryo. Dev. Biol., 2005, 288(1), 150-159.
[18]
Zhang, S.; Mercado-Uribe, I.; Xing, Z.; Sun, B.; Kuang, J.; Liu, J. Generation of cancer stem-like cells through the formation of polyploid giant cancer cells. Oncogene, 2014, 33(1), 116-128.
[19]
Lv, H.; Shi, Y.; Zhang, L.; Zhang, D.; Liu, G.; Yang, Z.; Li, Y.; Fei, F.; Zhang, S. Polyploid giant cancer cells with budding and the expression of cyclin E, S-phase kinase-associated protein 2, stathmin associated with the grading and metastasis in serous ovarian tumor. BMC Cancer, 2014, 14, 576.
[20]
Kondorosi, E.; Roudier, F.; Gendreau, E. Plant cell-size control: Growing by ploidy? Curr. Opin. Plant Biol., 2000, 3(6), 488-492.
[21]
Chen, S.; Stout, J.R.; Dharmaiah, S.; Yde, S.; Calvi, B.R.; Walczak, C.E. Transient endoreplication down-regulates the kinesin-14 HSET and contributes to genomic instability. Mol. Biol. Cell, 2016, 27(19), 2911-2923.
[22]
Erenpreisa, J.; Kalejs, M.; Cragg, M.S. Mitotic catastrophe and endomitosis in tumour cells: An evolutionary key to a molecular solution. Cell Biol. Int., 2005, 29(12), 1012-1018.
[23]
Niu, N.; Zhang, J.; Zhang, N.; Mercado-Uribe, I.; Tao, F.; Han, Z.; Pathak, S.; Multani, A.S.; Kuang, J.; Yao, J.; Bast, R.C.; Sood, A.K.; Hung, M.C.; Liu, J. Linking genomic reorganization to tumor initiation via the giant cell cycle. Oncogenesis, 2016, 5(12), e281.
[24]
Erenpreisa, J.A.; Cragg, M.S.; Fringes, B.; Sharakhov, I.; Illidge, T.M. Release of mitotic descendants by giant cells from irradiated Burkitt’s lymphoma cell line. Cell Biol. Int., 2000, 24(9), 635-648.
[25]
Sundaram, M.; Guernsey, D.L.; Rajaraman, M.M.; Rajaraman, R. Neosis: A novel type of cell division in cancer. Cancer Biol. Ther., 2004, 3(2), 207-218.
[26]
Walen, K.H. The origin of transformed cells. studies of spontaneous and induced cell transformation in cell cultures from marsupials, a snail, and human amniocytes. Cancer Genet. Cytogenet., 2002, 133(1), 45-54.
[27]
Rohnalter, V.; Roth, K.; Finkernagel, F.; Adhikary, T.; Obert, J.; Dorzweiler, K.; Bensberg, M.; Muller-Brusselbach, S.; Muller, R. A multi-stage process including transient polyploidization and EMT precedes the emergence of chemoresistent ovarian carcinoma cells with a dedifferentiated and pro-inflammatory secretory phenotype. Oncotarget, 2015, 6(37), 40005-40025.
[28]
Zack, T.I.; Schumacher, S.E.; Carter, S.L.; Cherniack, A.D.; Saksena, G.; Tabak, B.; Lawrence, M.S.; Zhsng, C.Z.; Wala, J.; Mermel, C.H.; Sougnez, C.; Gabriel, S.B.; Hernandez, B.; Shen, H.; Laird, P.W.; Getz, G.; Meyerson, M.; Beroukhim, R. Pan-cancer patterns of somatic copy number alteration. Nat. Genet., 2013, 45(10), 1134-1140.
[29]
Dikovskaya, D.; Cole, J.J.; Mason, S.M.; Nixon, C.; Karim, S.A.; McGarry, L.; Clark, W.; Hewitt, R.N.; Sammons, M.A.; Zhu, J.; Athineos, D.; Leach, J.D.; Marchesi, F.; van Tuyn, J.; Tait, S.W.; Brock, C.; Morton, J.P.; Wu, H.; Berger, S.L.; Blyth, K.; Adams, P.D. Mitotic stress is an integral part of the oncogene-induced senescence program that promotes multinucleation and cell cycle arrest. Cell Reports, 2015, 12(9), 1483-1496.
[30]
Mirzayans, R.; Andrais, B.; Scott, A.; Wang, Y.W.; Kumar, P.; Murray, D. Multinucleated giant cancer cells produced in response to ionizing radiation retain viability and replicate their genome. Int. J. Mol. Sci., 2017, 18(2), 360.
[31]
Sikora, E.; Mosieniak, G.; Sliwinska, M.A. Morphological and functional characteristic of senescent cancer cells. Curr. Drug Targets, 2016, 17(4), 377-387.
[32]
Ianzini, F.; Kosmacek, E.A.; Nelson, E.S.; Napoli, E.; Erenpreisa, J.; Kalejs, M.; Mackey, M.A. Activation of meiosis-specific genes is associated with depolyploidization of human tumor cells following radiation-induced mitotic catastrophe. Cancer Res., 2009, 69(6), 2296-2304.
[33]
Sharma, S.; Zeng, J.Y.; Zhuang, C.M.; Zhou, Y.Q.; Yao, H.P.; Hu, X.; Zhang, R.; Wang, M.H. Small-molecule inhibitor BMS-777607 induces breast cancer cell polyploidy with increased resistance to cytotoxic chemotherapy agents. Mol. Cancer Ther., 2013, 12(5), 725-736.
[34]
Lagadec, C.; Vlashi, E.; Della Donna, L.; Dekmezian, C.; Pajonk, F. Radiation-induced reprogramming of breast cancer cells. Stem Cells, 2012, 30(5), 833-844.
[35]
Jia, L.; Zhang, S.; Ye, Y.; Li, X.; Mercado-Uribe, I.; Bast, R.C., Jr; Liu, J. Paclitaxel inhibits ovarian tumor growth by inducing epithelial cancer cells to benign fibroblast-like cells. Cancer Lett., 2012, 326(2), 176-182.
[36]
Zhang, S.; Mercado-Uribe, I.; Liu, J. Tumor stroma and differentiated cancer cells can be originated directly from polyploid giant cancer cells induced by paclitaxel. Int. J. Cancer, 2014, 134(3), 508-518.
[37]
Ahn, H.J.; Kim, Y.S.; Kim, J.U.; Han, S.M.; Shin, J.W.; Yang, H.O. Mechanism of taxol-induced apoptosis in human SKOV3 ovarian carcinoma cells. J. Cell. Biochem., 2004, 91(5), 1043-1052.
[38]
Jordan, M.A.; Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer, 2004, 4(4), 253-265.
[39]
Ganem, N.J.; Cornils, H.; Chiu, S.Y.; O’Rourke, K.P.; Arnaud, J.; Yimlamai, D.; Thery, M.; Camargo, F.D.; Pellman, D. Cytokinesis failure triggers hippo tumor suppressor pathway activation. Cell, 2014, 158(4), 833-848.
[40]
Mosieniak, G.; Sikora, E. Polyploidy: The link between senescence and cancer. Curr. Pharm. Des., 2010, 16(6), 734-740.
[41]
Mosieniak, G.; Sliwinska, M.A.; Alster, O.; Strzeszewska, A.; Sunderland, P.; Piechota, M.; Was, H.; Sikora, E. Polyploidy formation in doxorubicin-treated cancer cells can favor escape from senescence. Neoplasia, 2015, 17(12), 882-893.
[42]
Puig, P.E.; Guilly, M.N.; Bouchot, A.; Droin, N.; Cathelin, D.; Bouyer, F.; Favier, L.; Ghiringhelli, F.; Kroemer, G.; Solary, E.; Martin, F.; Chauffert, B. Tumor cells can escape DNA-damaging cisplatin through DNA endoreduplication and reversible polyploidy. Cell Biol. Int., 2008, 32(9), 1031-1043.
[43]
Niu, N.; Mercado-Uribe, I.; Liu, J. Dedifferentiation into blastomere-like cancer stem cells via formation of polyploid giant cancer cells. Oncogene, 2017, 36(34), 4887.
[44]
Lu, X.; Kang, Y. Cell fusion as a hidden force in tumor progression. Cancer Res., 2009, 69(22), 8536-8539.
[45]
Rengstl, B.; Newrzela, S.; Heinrich, T.; Weiser, C.; Thalheimer, F.B.; Schmid, F.; Warner, K.; Hartmann, S.; Schroeder, T.; Kuppers, R.; Rieger, M.A.; Hansmann, M.L. Incomplete cytokinesis and re-fusion of small mononucleated Hodgkin cells lead to giant multinucleated Reed-Sternberg cells. Proc. Natl. Acad. Sci. USA, 2013, 110(51), 20729-20734.
[46]
Braune, E.B.; Tsoi, Y.L.; Phoon, Y.P.; Landor, S.; Silva Cascales, H.; Ramskold, D.; Deng, Q.; Lindqvist, A.; Lian, X.; Sahlgren, C.; Jin, S.B.; Lendahl, U. Loss of CSL unlocks a hypoxic response and enhanced tumor growth potential in breast cancer cells. Stem Cell Reports, 2016, 6(5), 643-651.
[47]
Mittal, K.; Donthamsetty, S.; Kaur, R.; Yang, C.; Gupta, M.V.; Reid, M.D.; Choi, D.H.; Rida, P.C.G.; Aneja, R. Multinucleated polyploidy drives resistance to Docetaxel chemotherapy in prostate cancer. Br. J. Cancer, 2017, 116(9), 1186-1194.
[48]
Walen, K.H. Mitosis is not the only distributor of mutated cells: non-mitotic endopolyploid cells produce reproductive genome-reduced cells. Cell Biol. Int., 2010, 34(8), 867-872.
[49]
Fujiwara, T.; Bandi, M.; Nitta, M.; Ivanova, E.V.; Bronson, R.T.; Pellman, D. Cytokinesis failure generating tetraploids promotes tumorigenesis in p53-null cells. Nature, 2005, 437(7061), 1043-1047.
[50]
Davoli, T.; de Lange, T. Telomere-driven tetraploidization occurs in human cells undergoing crisis and promotes transformation of mouse cells. Cancer Cell, 2012, 21(6), 765-776.
[51]
Leikam, C.; Hufnagel, A.L.; Otto, C.; Murphy, D.J.; Muhling, B.; Kneitz, S.; Nanda, I.; Schmid, M.; Wagner, T.U.; Haferkamp, S.; Brocker, E.B.; Schartl, M.; Meierjohann, S. In vitro evidence for senescent multinucleated melanocytes as a source for tumor-initiating cells. Cell Death Dis., 2015, 6, e1711.
[52]
Weihua, Z.; Lin, Q.; Ramoth, A.J.; Fan, D.; Fidler, I.J. Formation of solid tumors by a single multinucleated cancer cell. Cancer, 2011, 117(17), 4092-4099.
[53]
Kreso, A.; Dick, J.E. Evolution of the cancer stem cell model. Cell Stem Cell, 2014, 14(3), 275-291.
[54]
Mani, S.A.; Guo, W.; Liao, M.J.; Eaton, E.N.; Ayyanan, A.; Zhou, A.Y.; Brooks, M.; Reinhard, F.; Zhang, C.C.; Shipitsin, M.; Campbell, L.L.; Polyak, K.; Brisken, C.; Yang, J.; Weinberg, R.A. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell, 2008, 133(4), 704-715.
[55]
Jiang, Q.; Zhang, Q.; Wang, S.; Xie, S.; Fang, W.; Liu, Z.; Liu, J.; Yao, K. A fraction of CD133+ CNE2 cells is made of giant cancer cells with morphological evidence of asymmetric mitosis. J. Cancer, 2015, 6(12), 1236-1244.
[56]
Díaz-Carballo, D.; Saka, S.; Klein, J.; Rennkamp, T.; Acikelli, A.H.; Malak, S.; Jastrow, H.; Wennemuth, G.; Tempfer, C.; Schmitz, I.; Tannapfel, A.; Strumberg, D. A distinct oncogenerative multinucleated cancer cell serves as a source of stemness and tumor heterogeneity. Cancer Res., 2018, 78(9), 2318-2331.
[57]
Salmina, K.; Jankevics, E.; Huna, A.; Perminov, D.; Radovica, I.; Klymenko, T.; Ivanov, A.; Jascenko, E.; Scherthan, H.; Cragg, M.; Erenpreisa, J. Up-regulation of the embryonic self-renewal network through reversible polyploidy in irradiated p53-mutant tumour cells. Exp. Cell Res., 2010, 316(13), 2099-2112.
[58]
Chitikova, Z.V.; Gordeev, S.A.; Bykova, T.V.; Zubova, S.G.; Pospelov, V.A.; Pospelova, T.V. Sustained activation of DNA damage response in irradiated apoptosis-resistant cells induces reversible senescence associated with mTOR downregulation and expression of stem cell markers. Cell Cycle, 2014, 13(9), 1424-1439.
[59]
Ben-Porath, I.; Thomson, M.W.; Carey, V.J.; Ge, R.; Bell, G.W.; Regev, A.; Weinberg, R.A. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat. Genet., 2008, 40(5), 499-507.
[60]
Zhang, S.; Mercado-Uribe, I.; Liu, J. Generation of erythroid cells from fibroblasts and cancer cells in vitro and in vivo. Cancer Lett., 2013, 333(2), 205-212.
Call for Papers in Thematic Issues
31 December, 2025
Innovative Cancer Drug Targets: A New Horizon in Oncology
Cancer remains one of the most challenging diseases, with its complexity and adaptability necessitating continuous research efforts into more effective and targeted therapeutic approaches. Recent years have witnessed significant progress in understanding the molecular and genetic basis of cancer, leading to the identification of novel drug targets. These include, but ...read more
31 December, 2025
Role of Immune and Genotoxic Response Biomarkers in Tumor Microenvironment in Cancer Diagnosis and Treatment
Biological biomarkers have been used in medical research as an indicator of a normal or abnormal process inside the body, or of a disease. Nowadays, various researchers are in process of exploring and investigating the biological markers for the early assessment of cancer. DNA Damage response (DDR) pathways and immune ...read more
31 December, 2025
The Impact of Cancer Neuroscience on Novel Brain Cancer Treatment
Brain cancer remains one of the most challenging malignancies due to its complexity and resistance to conventional therapies. Recent advancements in cancer neuroscience have transformed our understanding of the brain's tumor microenvironment, offering promising insights into novel treatments. By studying the intricate interactions between cancer cells and the nervous system, ...read more
31 December, 2025
Unraveling the Tumor Microenvironment and Potential Therapeutic Targets: Insights from Single-Cell Sequencing and Spatial Transcriptomics
This special issue will focus on unraveling the complexities of the tumor microenvironment (TME) and identifying key biomarkers for potential therapeutic targets using advanced multi-omics techniques, such as single-cell sequencing and spatial transcriptomics. We seek original research and comprehensive reviews that investigate the heterogeneity and dynamics of the TME, emphasizing ...read more
Related Journals
Anti-Cancer Agents in Medicinal Chemistry
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry
Current Bioactive Compounds
Combinatorial Chemistry & High Throughput Screening
Current Cancer Therapy Reviews
Current Diabetes Reviews
Current Drug Safety
Current Drug Targets
Current Drug Therapy
Current Drug Delivery
Related Books
Anthocyanins: Pharmacology and Nutraceutical Importance
The Roles and Responsibilities of Clinical Pharmacists in Hospital Settings
Bioactive Compounds from Medicinal Plants for Cancer Therapy and Chemoprevention
Drug Addiction Mechanisms in the Brain
Software and Programming Tools in Pharmaceutical Research
Objective Pharmaceutics: A Comprehensive Compilation of Questions and Answers for Pharmaceutics Exam Prep
Medicinal Chemistry of Drugs Affecting Cardiovascular and Endocrine Systems
Frontiers in Clinical Drug Research - Anti-Cancer Agents
The Management of Metastatic Triple-Negative Breast Cancer: An Integrated and Expeditionary Approach
Advanced Pharmacy
Article Metrics
374
39